공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 MRD(미세잔존질환) 검사 시장(2020-2025년) : 시장 예측(기술, 용도, 최종사용자, 지역별), 경쟁 분석

Global MRD Testing Market: Focus on Technology, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2025

리서치사 BIS Research Inc.
발행일 2020년 12월 상품 코드 980840
페이지 정보 영문
가격
US $ 5,000 ₩ 5,800,000 PDF (Single User License/1-3 Users)
US $ 8,000 ₩ 9,280,000 PDF and Excel (Global License)


세계의 MRD(미세잔존질환) 검사 시장(2020-2025년) : 시장 예측(기술, 용도, 최종사용자, 지역별), 경쟁 분석 Global MRD Testing Market: Focus on Technology, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2025
발행일 : 2020년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 MRD(미세잔존질환) 검사 시장 규모는 예측기간 중 15.64%의 CAGR로 성장할 것으로 예측됩니다. 혈액 악성 종양 발증률 상승, 맞춤형 치료에 대한 소비자의 인지도 상승, 국립 암연구소로부터의 연구 자금 증가, 신흥 경제 국가의 가처분 소득 증가 등의 요인이 시장 성장을 추진하고 있습니다.

세계의 MRD(미세잔존질환) 검사 시장을 조사했으며, 시장 정의와 개요, 신종 코로나바이러스 감염증(COVID-19) 및 기타 시장 영향요인 분석, 규제·승인·상환·자금 조달 등의 시나리오, 정부에 의한 이니셔티브, 시장 규모 추정과 예측, 기술·용도·최종사용자·지역/주요 국가 등 각종 세분화별 내역, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.

주요 요약

제1장 제품 정의와 시장 범위

제2장 조사 방법

제3장 시장 개요

제4장 시장 역학

  • 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제5장 산업 분석

  • 승인 시나리오
  • 자금 조달 시나리오
  • 규제 체계
  • 상환 시나리오
  • 공급망 분석
  • 정부에 의한 이니셔티브
  • COVID-19의 영향
  • 가격 민감도 분석

제6장 경쟁 분석

  • 개요
  • 공동 대처
  • 승인
  • 제품 발매·업데이트
  • 기타
  • 시장 점유율 분석
  • 성장 점유율 분석
    • 기업별
    • 기술별
    • 용도별
    • 최종사용자별

제7장 시장 분석과 예측 : 기술별

  • 개요
  • 유세포 분석
  • 중합효소 연쇄 반응(PCR)
  • 차세대 시퀀싱(NGS)
  • 기타

제8장 시장 분석과 예측 : 용도별

  • 개요
  • 혈액 악성 종양
    • 비호지킨 림프종(NHL)
    • 다발성 골수종(MM)
    • 급성 림프아구성 백혈병(ALL)
    • 만성 림프구성 백혈병(CLL)
    • 급성 골수성 백혈병(AML)
    • 만성 골수성 백혈병(CML)
    • 호지킨 림프종(HL)
    • 기타

제9장 시장 분석과 예측 : 최종사용자별

  • 개요
  • 전문 클리닉·병원
  • 진단 실험실
  • 연구기관
  • 기타

제10장 시장 분석과 예측 : 지역·주요 국가별

  • 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 이탈리아
    • 프랑스
    • 영국
    • 스페인
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 싱가포르
    • 기타
  • 라틴아메리카·중동
    • 브라질
    • 멕시코
    • 사우디아라비아
    • 기타
  • 기타 지역

제11장 기업 개요

  • ICON plc
  • ArcherDX, Inc.
  • ARUP Laboratories
  • ASURAGEN INC.
  • Cergentis B.V.
  • Bio-Rad Laboratories, Inc.
  • Mission Bio, Inc.
  • Guardant Health
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Inivata Ltd.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Opko Health, Inc.
  • Quest Diagnostics Incorporated
  • Sysmex Corporation
  • Adaptive Biotechnologies Corporation
KSM 21.01.18

List of Tables

  • Table 4.1: Likert Scale
  • Table 4.2: Impact Analysis of Market Drivers
  • Table 4.3: Impact Analysis of Market Restraints
  • Table 5.1: List of Approved MRD Tests by Major Players
  • Table 5.2: List of Launched MRD Tests by Major Players
  • Table 5.3: Key Notable Developments
  • Table 5.4: Comparison of FDA and EMA Draft Guidance
  • Table 5.5: Registration Criteria for IVD Medical Devices as per CFDA
  • Table 5.6: Key Coverage Providers for Hematologic Malignancies Testing
  • Table 7.1: Key Products Offered Based on Flow Cytometry
  • Table 7.2: Key Products Offered Based on PCR
  • Table 7.3: Key Products Offered Based on NGS

List of Figures

  • Figure 1: Incidence of Age-Standardized Incident Rates for Cancer Globally, 2020
  • Figure 2: Relative Percent of New Lymphomas Expected in U.S. in 2020
  • Figure 3: Prevalence of Different Hematological Malignancies Across U.S. (2013-2017)
  • Figure 4: Impact Analysis on the Global Minimal Residual Disease Testing Market
  • Figure 5: Global MRD Testing Market (by Application), $Million, 2019 vs. 2025
  • Figure 6: Global MRD Testing Market (by Hematological Malignancy), $Million, 2019 vs. 2025
  • Figure 7: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2019 vs. 2025
  • Figure 8: Global Minimal Residual Disease Testing Market (by End User), $Million, 2019 vs. 2025
  • Figure 9: Global Minimal Residual Disease Testing Market Snapshot
  • Figure 1.1: Global MRD Testing Market Segments
  • Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.1: Global MRD Testing Market, $Million, 2018-2025
  • Figure 3.2: Global MRD Testing Market Potential, $Million, 2019-2025
  • Figure 4.1: Global Incidence and Mortality Rate for Individual Hematological Conditions (2016)
  • Figure 4.2: Estimated New Cases of Hematological Cancer, 2020
  • Figure 5.3: Laboratory Methods for MRD Detection
  • Figure 5.4: Classification on In-Vitro Diagnostics in India
  • Figure 5.5: Methods to Achieve Coverage
  • Figure 5.6: Supply Chain Analysis of Laboratory Developed Tests
  • Figure 5.7: Supply Chain Analysis of In-Vitro Diagnostics
  • Figure 6.1: Share of Key Developments and Strategies, January 2018-December 2020
  • Figure 6.2: Synergistic Activities Share (by Company), January 2018-December 2020
  • Figure 6.3: Market Share Analysis for Global MRD Testing Market, 2018 and 2019
  • Figure 6.4: Growth Share Analysis for Global MRD Testing Market (by Company), 2019
  • Figure 6.5: Growth Share Analysis for Global MRD Testing Market (by Technology), 2019-2025
  • Figure 6.6: Growth Share Analysis for Global MRD Testing Market (by Application), 2019-2025
  • Figure 6.7: Growth Share Analysis for Global MRD Testing Market (by End User), 2019-2025
  • Figure 7.1: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2019-2025
  • Figure 7.2: Global Minimal Residual Disease Testing Market (by Flow Cytometry), $Million, 2019-2025
  • Figure 7.3: Global Minimal Residual Disease Testing Market (PCR), $Million, 2019-2025
  • Figure 7.4: Global Minimal Residual Disease Testing Market (NGS), $Million, 2019-2025
  • Figure 7.5: Global Minimal Residual Disease Testing Market (Other Technologies), $Million, 2019-2025
  • Figure 8.1: Global MRD Testing Market (by Application)
  • Figure 8.2: Global MRD Testing Market (by Application), 2019-2025
  • Figure 8.3: Global MRD Testing Market (by Hematological Malignancies), 2019 vs. 2025
  • Figure 8.4: Global Minimal Residual Disease Testing Market (Non-Hodgkin's Lymphoma), $Million, 2019-2025
  • Figure 8.5: Global Minimal Residual Disease Testing Market (by Non-Hodgkin's Lymphoma Type), $Million, 2019-2025
  • Figure 8.6: Global NHL MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.7: Global Minimal Residual Disease Testing Market (Multiple Myeloma), $Million, 2019-2025
  • Figure 8.8: Global MM-MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.9: Global Minimal Residual Disease Testing Market (Acute Lymphoblastic Leukemia), $Million, 2019-2025
  • Figure 8.10: Global ALL-MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.11: Global Minimal Residual Disease Testing Market (Chronic Lymphocytic Leukemia), $Million, 2019-2025
  • Figure 8.12: Global CLL-MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.13: Global Minimal Residual Disease Testing Market (Acute Myeloid Leukemia), $Million, 2019-2025
  • Figure 8.14: Global AML-MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.15: Global Minimal Residual Disease Testing Market (Chronic Myeloid Leukemia), $Million, 2019-2025
  • Figure 8.16: Global CML-MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.17: Global Minimal Residual Disease Testing Market (Hodgkin's Lymphoma), $Million, 2019-2025
  • Figure 8.18: Global HL-MRD Testing Market (by Age), $Million, 2019-2025
  • Figure 8.19: Global Minimal Residual Disease Testing Market (Other Leukemia), $Million, 2019-2025
  • Figure 9.1: Global Minimal Residual Disease Testing Market (by End User), $Million, 2019-2025
  • Figure 9.2: Specialty Clinics and Hospitals Market, $Million, 2019-2025
  • Figure 9.3: Diagnostic Laboratories Market, $Million, 2019-2025
  • Figure 9.4: Research Institutions Market, $Million, 2019-2025
  • Figure 9.5: Global Minimal Residual Disease Testing Market (Other End Users), $Million, 2019-2025
  • Figure 10.1: Global Minimal Residual Disease Testing Market (by Region), $Million, 2019 and 2025
  • Figure 10.2: North America: Market Dynamics
  • Figure 10.3: North America Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.4: North America Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
  • Figure 10.5: U.S. Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.6: U.S. Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.7: Growth-Share Analysis for U.S. Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.8: Canada Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.9: Canada Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.10: Growth-Share Analysis for Canada Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.11: Europe: Market Dynamics
  • Figure 10.12: Europe Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.13: Europe Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
  • Figure 10.14: Germany Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.15: Germany Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.16: Growth-Share Analysis for Germany Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.17: Italy Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.18: Italy Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.19: Growth-Share Analysis for Italy Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.20: France Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.21: France Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.22: Growth-Share Analysis for France Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.23: U.K. Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.24: U.K. Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.25: Growth-Share Analysis for U.K. Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.26: Spain Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.27: Spain Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.28: Growth-Share Analysis for Spain Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.29: Rest-of-Europe Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.30: Rest-of-Europe Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.31: Growth-Share Analysis for Rest-of-Europe Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.32: Asia-Pacific: Market Dynamics
  • Figure 10.33: Asia-Pacific Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.34: Asia-Pacific Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
  • Figure 10.35: China Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.36: China Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.37: Growth-Share Analysis for China Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.38: India Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.39: India Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.40: Growth-Share Analysis for India Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.41: Japan Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.42: Japan Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.43: Growth-Share Analysis for Japan Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.44: South Korea Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.45: South Korea Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.46: Growth Share Analysis for South Korea MRD Testing Market (by Application), 2019-2025
  • Figure 10.47: Australia Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.48: Australia Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.49: Growth-Share Analysis for Australia Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.50: Number of Death in Australia by Leukemia (2012-2017)
  • Figure 10.51: Singapore Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.52: Singapore Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.53: Growth-Share Analysis for Singapore Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.54: Rest-of-APAC Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.55: Rest-of-APAC Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.56: Growth-Share Analysis for Rest-of-APAC Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.57: Latin America: Market Dynamics
  • Figure 10.58: Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.59: Latin America and Middle East Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
  • Figure 10.60: Brazil Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.61: Brazil Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.62: Growth-Share Analysis for Brazil Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.63: Mexico Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.64: Mexico Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.65: Growth-Share Analysis for Mexico Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.66: Saudi Arabia Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.67: Saudi Arabia Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.68: Growth-Share Analysis for Saudi Arabia Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.69: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.70: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.71: Growth-Share Analysis for Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 10.72: Rest-of-the-World Minimal Residual Disease Testing Market, $Million, 2019-2025
  • Figure 10.73: Rest-of-the-World Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
  • Figure 10.74: Growth-Share Analysis for Rest-of-the-World Minimal Residual Disease Testing Market (by Application), 2019-2025
  • Figure 11.1: ICON plc: Overall Product Portfolio
  • Figure 11.2: ICON plc: Overall Financials, 2017-2019
  • Figure 11.3: ICON plc: Revenue (by Region), 2017-2019
  • Figure 11.5: ArcherDX, Inc.: Portfolio
  • Figure 11.6: ArcherDX, Inc.: SWOT Analysis
  • Figure 11.7: ARUP Laboratories: Product Portfolio
  • Figure 11.8: ARUP Laboratories: SWOT Analysis
  • Figure 11.9: ASURAGEN INC.: Product Portfolio
  • Figure 11.10: ASURAGEN INC.: SWOT Analysis
  • Figure 11.11: Cergentis B.V.: Product Portfolio
  • Figure 11.12: Cergentis B.V.: SWOT Analysis
  • Figure 11.13: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 11.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 11.15: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 11.19: Mission Bio, Inc.: Product Portfolio
  • Figure 11.20: Mission Bio, Inc.: SWOT Analysis
  • Figure 11.21: Guardant Health: Portfolio
  • Figure 11.22: Guardant Health: Overall Financials, 2017-2019
  • Figure 11.23: Guardant Health: Revenue (by Segment), 2017-2019
  • Figure 11.24: Guardant Health: Revenue (by Region), 2017-2019
  • Figure 11.25: Guardant Health: SWOT Analysis
  • Figure 11.26: Invivoscribe, Inc.: Product Portfolio
  • Figure 11.27: Invivoscribe, Inc.: SWOT Analysis
  • Figure 11.28: Laboratory Corporation of America Holdings: Product Portfolio
  • Figure 11.29: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 11.30: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 11.31: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 11.32: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 11.33: Inivata Ltd.: Product Portfolio
  • Figure 11.34: Inivata Ltd.: SWOT Analysis
  • Figure 11.35: Natera, Inc.: Portfolio
  • Figure 11.36: Natera, Inc.: Overall Financials, 2017-2019
  • Figure 11.37: Natera, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.38: Natera, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.39: Natera, Inc.: SWOT Analysis
  • Figure 11.40: NeoGenomics Laboratories, Inc.: Portfolio
  • Figure 11.41: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 11.42: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.43: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.44: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 11.45: Opko Health: Portfolio
  • Figure 11.46: Opko Health, Inc.: Overall Financials, 2017-2019
  • Figure 11.47: Opko Health, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.48: Opko Health, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.49: Opko Health, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.50: Opko Health, Inc.: SWOT Analysis
  • Figure 11.51: Quest Diagnostics Incorporated: Product Portfolio
  • Figure 11.52: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 11.53: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 11.54: Sysmex Corporation: Product Portfolio
  • Figure 11.55: Sysmex Corporation: Overall Financials, 2017-2019
  • Figure 11.56: Sysmex Corporation: Revenue (by Business Segment), 2018-2019
  • Figure 11.57: Sysmex Corporation R&D Expenditure, 2017-2019
  • Figure 11.58: Sysmex Corporation: SWOT Analysis
  • Figure 11.59: Adaptive Biotechnologies Corporation: Product Portfolio
  • Figure 11.60: Adaptive Biotechnologies Corporation: Overall Financials, 2017-2019
  • Figure 11.61: Adaptive Biotechnologies Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 11.62: Adaptive Biotechnologies Corporation R&D Expenditure, 2017-2019
  • Figure 11.63: Adaptive Biotechnologies Corporation: SWOT Analysis

"Global MRD Testing Market to Grow at a CAGR of 15.64% from 2020-2025."

Market Report Coverage - MRD Testing

Market Segmentation

  • Technology - Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Other Technologies
  • Application - Hematological Malignancies (Non-Hodgkin's Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia Leukemia, Hodgkin's Lymphoma, and Other Leukemia) and Solid Tumor
  • End User - Specialty Clinics and Hospitals, Diagnostic Laboratories, Research Institutions, and Other End Users

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, Italy, France, U.K., Spain, and Rest-of-Europe
  • Asia-Pacific - China, India, Japan, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
  • Latin America & Middle East - Brazil, Mexico, Saudi Arabia, and Rest-of-Latin America and Middle East
  • Rest-of-the-World

Growth Drivers

  • Rising Incidence of Hematologic Malignancies
  • Increasing Consumer Awareness for Tailored Therapy
  • Increase in Research Funding from National Cancer Institute
  • Increasing Disposable Income in Emerging Economies

Market Challenges

  • False Negatives and Positives
  • Uncertain Reimbursement and Regulatory Policies
  • Lack of Trained Professionals
  • Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies

Market Opportunities

  • Potential Long-Term Cost Savings
  • Increasing Market Access in Emerging Economies
  • Technological Evolution of Testing

Key Companies Profiled

ICON plc, ArcherDX, Inc. (Part of Invitae Corporation), Arup Laboratories, ASURAGEN INC., Cergentis B.V., Bio-Rad Laboratories, Inc., Mission Bio, Inc., Guardant Health, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Inivata Ltd., Natera, Inc., NeoGenomics Laboratories, Inc., Opko Health, Inc., Quest Diagnostics Incorporated, Sysmex Corporation, Adaptive Biotechnologies Corporation.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities and their respective impacts in the global MRD testing market?
  • What is the potential impact of biotechnological advancement in the diagnostic industry among end users, such as physicians, researchers, pathologists, and laboratory technicians?
  • What is the current market demand along with future expected demand for the global MRD testing market?
  • Has MRD testing penetrated major countries facing an immense burden from hematological malignancies?
  • What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?
  • What are the key development strategies that are implemented by the major players in order to sustain in the competitive market?
  • How is each segment of the market expected to grow during the forecast period from 2020 to 2025 based on each segment?
    • Technology (flow cytometry, PCR, NGS, and other technologies)
    • Application (hematological malignancy and solid tumor)
    • End user (specialty clinics and hospitals, diagnostic laboratories, research institutions, and other end users)
    • Region (North America, Europe, Asia-Pacific, Latin America & Middle East, and Rest-of-the-World)
  • Which are the leading players with significant offerings to the global MRD testing market? What is the expected market dominance for each of these leading players?
  • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global MRD testing market?

Market Overview

Our healthcare experts have found the MRD Testing industry to be one of the most rapidly evolving and dynamic markets. The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period, 2020-2025. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, the increasing consumer awareness for tailored therapy, the increasing research funding from the National Cancer Institute, and the increasing disposable income in emerging economies.

The market is favored by the developments in the field of MRD testing solutions for hematologic malignancies and solid tumors. Currently, the MRD testing industry is witnessing an upsurge due to the rising incidence of hematologic malignancies, resulting in the high demand for sensitive testing solutions. Additionally, the high adoption of MRD tests among patients and the growing awareness among physicians regarding MRD testing are some of the critical factors expected to bolster the market growth.

Furthermore, diagnostic companies are focusing on the development of NGS-based MRD tests for lymphoid malignancies, having higher sensitivity and low turnaround time to benefit the patients suffering from hematologic malignancies.

Within the research report, the market is segmented on the basis of technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of cases associated with hematological malignancies has created a buzz among the diagnostic companies to further invest in the development of reliable, sensitive, and rapid MRD testing solutions to aid patients to get into remission. Due to the presence of a diverse product portfolio and intense market penetration, Invivoscribe, Inc. has been a pioneer in this field and has been a significant competitor in this market.

On the basis of region, North America holds the largest share of the MRD testing market due to high infusion of funding from government organizations for conducting research on hematological malignancies, rising incidence of hematological malignancies, and high adoption of technologically advanced MRD tests, among others. Apart from this, Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period, 2020-2025.

Table of Contents

Executive Summary

1 Product Definition and Market Scope

  • 1.1 Inclusion and Exclusion
  • 1.2 Scope of Work
  • 1.3 Key Questions Answered in the Report

2 Research Methodology

  • 2.1 Primary Data Sources
  • 2.2 Secondary Data Sources
  • 2.3 Market Estimation Model
  • 2.4 Criteria for Company Profiling

3 Market Overview

  • 3.1 MRD Testing
  • 3.2 MRD Testing: Solid Tumor vs Hematological Malignancies
  • 3.3 Market Footprint
  • 3.4 Market Size and Future Growth Potential

4 Market Dynamics

  • 4.1 Impact Analysis
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Hematologic Malignancies
    • 4.2.2 Increasing Consumer Awareness for Tailored Therapy
    • 4.2.3 Increase in Research Funding from National Cancer Institute
    • 4.2.4 Increasing Disposable Income in Emerging Economies
  • 4.3 Market Restraints
    • 4.3.1 False Negatives and Positives
    • 4.3.2 Uncertain Reimbursement and Regulatory Policies
    • 4.3.3 Lack of Trained Professionals
    • 4.3.4 Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies
  • 4.4 Market Opportunities
    • 4.4.1 Potential Long-Term Cost Savings
    • 4.4.2 Increasing Market Access in Emerging Economies
    • 4.4.3 Technological Evolution of Testing
      • 4.4.3.1 8- and 10-Color Flow Cytometry
      • 4.4.3.2 PCR for Gene Rearrangements
      • 4.4.3.3 NGS and Multiplexing

5 Industry Insights

  • 5.1 Approval Scenario
    • 5.1.1 Approved Minimal Residual Disease Tests by Major Players
    • 5.1.2 Launched Minimal Residual Disease Tests by Major Players
  • 5.2 Financing Scenario
    • 5.2.1 Key Players Stratification (as Per Raised Financing Value)
    • 5.2.2 Key Players Financing Analysis (FY2017-2019)
  • 5.3 Regulatory Framework
    • 5.3.1 Legal Requirements and Framework in U.S.
    • 5.3.2 Legal Requirements and Framework in Europe
    • 5.3.3 Legal Requirements and Framework in Asia-Pacific
      • 5.3.3.1 Japan
      • 5.3.3.2 China
      • 5.3.3.3 India
  • 5.4 Reimbursement Scenario
    • 5.4.1 North America
      • 5.4.1.1 OPD vs IPD
    • 5.4.2 European Union
      • 5.4.2.1 OPD vs IPD
    • 5.4.3 Asia-Pacific
  • 5.5 Supply Chain Analysis
    • 5.5.1 For Laboratory Developed Tests (LDTs)
    • 5.5.2 For In-Vitro Diagnostics (IVDs)
  • 5.6 Minimal Residual Disease Testing Government Initiatives
    • 5.6.1 Technology Consideration for Minimal Residual Disease
      • 5.6.1.1 Considerations for Cellular Technology Platforms
      • 5.6.1.2 Considerations for Molecular Technology Platforms
      • 5.6.1.3 Considerations for Sample
  • 5.7 Impact of COVID-19 on Minimal Residual Disease Testing Market
    • 5.7.1 Considerations With Inpatients
    • 5.7.2 Considerations With Outpatients
  • 5.8 Price Sensitivity Analysis (Elasticity)
    • 5.8.1 Physicians' Perception
      • 5.8.1.1 Turnaround Time (TAT)
      • 5.8.1.2 Test Sensitivity
    • 5.8.2 Investors' Perception
      • 5.8.2.1 Turnaround Time (TAT)
      • 5.8.2.2 Test Sensitivity
    • 5.8.3 Payors' Perception
      • 5.8.3.1 Turnaround Time (TAT)
      • 5.8.3.2 Test Sensitivity

6 Global Minimal Residual Disease Testing Market: Competitive Insights

  • 6.1 Overview
  • 6.2 Synergistic Activities
  • 6.3 Approvals
  • 6.4 Product Launches and Updates
  • 6.5 Other Developments
  • 6.6 Market Share Analysis, 2018-2019
  • 6.7 Growth Share Analysis
    • 6.7.1 Growth Share Analysis (by Company)
    • 6.7.2 Growth Share Analysis (by Technology)
    • 6.7.3 Growth Share Analysis (by Application)
    • 6.7.4 Growth Share Analysis (by End User)

7 Global Minimal Residual Disease Testing Market (by Technology), 2019-2025

  • 7.1 Overview
  • 7.2 Flow Cytometry
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Next-Generation Sequencing (NGS)
  • 7.5 Other Technologies

8 Global Minimal Residual Testing Market (by Application), 2019-2025

  • 8.1 Overview
  • 8.2 Hematological Malignancies
    • 8.2.1 Non-Hodgkin's Lymphoma (NHL)
      • 8.2.1.1 Non-Hodgkin's Lymphoma (NHL) (by Type)
      • 8.2.1.2 Non-Hodgkin's Lymphoma (NHL) (by Age)
    • 8.2.2 Multiple Myeloma (MM)
      • 8.2.2.1 Multiple Myeloma (MM) (by Age)
    • 8.2.3 Acute Lymphoblastic Leukemia (ALL)
      • 8.2.3.1 Acute Lymphoblastic Leukemia (ALL) (by Age)
    • 8.2.4 Chronic Lymphocytic Leukemia (CLL)
      • 8.2.4.1 Chronic Lymphocytic Leukemia (CLL) (by Age)
    • 8.2.5 Acute Myeloid Leukemia (AML)
      • 8.2.5.1 Acute Myeloid Leukemia (AML) (by Age)
    • 8.2.6 Chronic Myeloid Leukemia (CML)
      • 8.2.6.1 Chronic Myeloid Leukemia (CML) (by Age)
    • 8.2.7 Hodgkin's Lymphoma (HL)
      • 8.2.7.1 Hodgkin's Lymphoma (HL) (by Age)
    • 8.2.8 Other Leukemia

9 Global Minimal Residual Disease Testing Market (by End User), 2019-2025

  • 9.1 Overview
  • 9.2 Specialty Clinics and Hospitals
  • 9.3 Diagnostic Laboratories
  • 9.4 Research Institutions
  • 9.5 Other End Users

10 Global Minimal Residual Disease Testing Market (by Region), 2019-2025

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
      • 10.2.1.1 U.S. Minimal Residual Disease Testing Market (by Application)
    • 10.2.2 Canada
      • 10.2.2.1 Canada Minimal Residual Disease Testing Market (by Application)
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Germany Minimal Residual Disease Testing Market (by Application)
    • 10.3.2 Italy
      • 10.3.2.1 Italy Minimal Residual Disease Testing Market (by Application)
    • 10.3.3 France
      • 10.3.3.1 France Minimal Residual Disease Testing Market (by Application)
    • 10.3.4 U.K.
      • 10.3.4.1 U.K. Minimal Residual Disease Testing Market (by Application)
    • 10.3.5 Spain
      • 10.3.5.1 Spain Minimal Residual Disease Testing Market (by Application)
    • 10.3.6 Rest-of-Europe
      • 10.3.6.1 Rest-of-Europe Minimal Residual Disease Testing Market (by Application)
  • 10.4 Asia-Pacific
    • 10.4.1 China
      • 10.4.1.1 China Minimal Residual Disease Testing Market (by Application)
    • 10.4.2 India
      • 10.4.2.1 India Minimal Residual Disease Testing Market (by Application)
    • 10.4.3 Japan
      • 10.4.3.1 Japan Minimal Residual Disease Testing Market (by Application)
    • 10.4.4 South Korea
      • 10.4.4.1 South Korea MRD Testing Market (by Application)
    • 10.4.5 Australia
      • 10.4.5.1 Australia Minimal Residual Disease Testing Market (by Application)
    • 10.4.6 Singapore
      • 10.4.6.1 Singapore Minimal Residual Disease Testing Market (by Application)
    • 10.4.7 Rest-of-APAC (RoAPAC)
      • 10.4.7.1 Rest-of-APAC Minimal Residual Disease Testing Market (by Application)
  • 10.5 Latin America and Middle East
    • 10.5.1 Brazil
      • 10.5.1.1 Brazil Minimal Residual Disease Testing Market (by Application)
    • 10.5.2 Mexico
      • 10.5.2.1 Mexico Minimal Residual Disease Testing Market (by Application)
    • 10.5.3 Saudi Arabia
      • 10.5.3.1 Saudi Arabia Minimal Residual Disease Testing Market (by Application)
    • 10.5.4 Rest-of-Latin America and Middle East
      • 10.5.4.1 Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application)
  • 10.6 Rest-of-the-World (RoW)
      • 10.6.1.1 Rest-of-the-World Minimal Residual Disease Testing Market (by Application)

11 Company Profiles

  • 11.1 ICON plc
    • 11.1.1 Company Overview
    • 11.1.2 Role of ICON plc in Global Minimal Residual Disease Testing Market
    • 11.1.3 Financials
    • 11.1.4 SWOT Analysis
  • 11.2 ArcherDX, Inc. (Part of Invitae Corporation)
    • 11.2.1 Company Overview
    • 11.2.2 Role of ArcherDX, Inc. in Global Minimal Residual Disease Testing Market
    • 11.2.3 SWOT Analysis
  • 11.3 ARUP Laboratories
    • 11.3.1 Company Overview
    • 11.3.2 Role of ARUP Laboratories in Global Minimal Residual Disease Testing Market
    • 11.3.3 SWOT Analysis
  • 11.4 ASURAGEN INC.
    • 11.4.1 Company Overview
    • 11.4.2 Role of ASURAGEN Inc. in Global Minimal Residual Disease Testing Market
    • 11.4.3 SWOT Analysis
  • 11.5 Cergentis B.V.
    • 11.5.1 Company Overview
    • 11.5.2 Role of Cergentis B.V. in Global Minimal Residual Disease Testing Market
    • 11.5.3 SWOT Analysis
  • 11.6 Bio-Rad Laboratories, Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Role of Bio-Rad Laboratories, Inc. in Global Minimal Residual Disease Testing Market
    • 11.6.3 Financials
    • 11.6.4 Key Insights About Financial Health of the Company
    • 11.6.5 SWOT Analysis
  • 11.7 Mission Bio, Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Role of Mission Bio, Inc. in Global Minimal Residual Disease Testing Market
    • 11.7.3 SWOT Analysis
  • 11.8 Guardant Health
    • 11.8.1 Company Overview
    • 11.8.2 Role of Guardant Health in Global Minimal Residual Disease Testing Market
    • 11.8.3 Financials
    • 11.8.4 SWOT Analysis
  • 11.9 Invivoscribe, Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Role of Invivoscribe, Inc. in Global Minimal Residual Disease Testing Market
    • 11.9.3 SWOT Analysis
  • 11.1 Laboratory Corporation of America Holdings
    • 11.10.1 Company Overview
    • 11.10.2 Role of Laboratory Corporation of America Holdings in Global Minimal Residual Disease Testing Market
    • 11.10.3 Financials
    • 11.10.4 SWOT Analysis
  • 11.11 Inivata Ltd.
    • 11.11.1 Company Overview
    • 11.11.2 Role of Inivata Ltd. in Global Minimal Residual Disease Testing Market
    • 11.11.3 SWOT Analysis
  • 11.12 Natera, Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Role of Natera, Inc. in Global Minimal Residual Testing Market
    • 11.12.3 Financials
    • 11.12.4 Key Insights About Financial Health of the Company
    • 11.12.5 SWOT Analysis
  • 11.13 NeoGenomics Laboratories, Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Role of NeoGenomics Laboratories, Inc. in Global Minimal Residual Testing Market
    • 11.13.3 Financials
    • 11.13.4 Key Insights About Financial Health of the Company
    • 11.13.5 SWOT Analysis
  • 11.14 Opko Health, Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Role of Opko Health, Inc. in Global Minimal Residual Disease Testing Market
    • 11.14.3 Financials
    • 11.14.4 Key Insights About Financial Health of the Company
    • 11.14.5 SWOT Analysis
  • 11.15 Quest Diagnostics Incorporated
    • 11.15.1 Company Overview
    • 11.15.2 Role of Quest Diagnostics Incorporated in Global Minimal Residual Disease Testing Market
    • 11.15.3 Financials
    • 11.15.4 SWOT Analysis
  • 11.16 Sysmex Corporation
    • 11.16.1 Company Overview
    • 11.16.2 Role of Sysmex Corporation in Global Minimal Residual Disease Testing Market
    • 11.16.3 Financials
    • 11.16.4 Key Insights About Financial Health of the Company
    • 11.16.5 SWOT Analysis
  • 11.17 Adaptive Biotechnologies Corporation
    • 11.17.1 Company Overview
    • 11.17.2 Role of Adaptive Biotechnologies Corporation in Global Minimal Residual Disease Testing Market
    • 11.17.3 Financials
    • 11.17.4 Key Insights About Financial Health of the Company
    • 11.17.5 SWOT Analysis
Back to Top
전화 문의
F A Q